Regulus Therapeutics Analyst Ratings
Regulus Therapeutics Analyst Ratings
Buy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429
Regulus Therapeutics Analyst Ratings
Optimistic Buy Rating for Regulus Therapeutics' RGLS8429 Amid Promising ADPKD Treatment Progress
Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones
Regulus Therapeutics Analyst Ratings
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11
Regulus Therapeutics Analyst Ratings
Buy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Data
Regulus Therapeutics Analyst Ratings
Regulus Therapeutics Analyst Ratings
Wells Fargo Maintains Equal-Weight on Regulus Therapeutics, Raises Price Target to $3
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Regulus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Regulus Therapeutics Analyst Ratings
Regulus Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
No Data